Heron Therapeutics traded at $2.71 this Tuesday January 31st, increasing $0.04 or 1.50 percent since the previous trading session. Looking back, over the last four weeks, Heron Therapeutics gained 11.52 percent. Over the last 12 months, its price fell by 69.17 percent. Looking ahead, we forecast Heron Therapeutics to be priced at 2.70 by the end of this quarter and at 2.44 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 8,025.00 13.00 0.16% 36.43%
ALKERMES 28.64 -0.15 -0.52% 13.34%
Alnylam Pharmaceuticals 226.40 1.00 0.44% 56.21%
Amarin 1.86 0.05 2.76% -50.13%
Anika Therapeutics 31.01 0.94 3.13% -1.56%
ANI Pharmaceuticals 44.73 1.98 4.63% 13.67%
Arrowhead Research 34.99 1.71 5.14% -36.50%
Emergent BioSolutions 13.19 0.27 2.09% -71.96%
Endo International 0.09 -0.0001 -0.11% -97.04%
Esperion Therapeutics 6.36 -0.14 -2.15% 43.57%
GlaxoSmithKline 1,427.60 14.60 1.03% -13.17%
Heron Therapeutics 2.71 0.04 1.50% -69.17%
Immunogen 4.60 0.09 2.00% -20.28%
Insmed 21.53 0.57 2.72% -9.19%
Jazz Pharmaceuticals 156.66 2.89 1.88% 11.27%
Ligand Pharmaceuticals 69.70 1.54 2.26% -43.12%
Merck & Co 107.41 1.32 1.24% 31.12%
Neurocrine Biosciences 110.93 2.64 2.44% 40.03%
Nektar Therapeutics 2.72 0.11 4.21% -75.41%
Omeros 2.90 0.06 2.11% -54.69%
Pacira 39.27 0.39 1.00% -37.06%
Ultragenyx Pharmaceutical 45.33 2.35 5.47% -37.08%
Regeneron Pharmaceuticals 758.01 22.01 2.99% 23.58%
Roche Holding 285.40 -2.80 -0.97% -20.62%
Sangamo BioSciences 3.49 0.09 2.65% -43.16%
Surmodics 28.11 0.21 0.75% -38.11%
Teva Pharmaceutical Industries 10.54 0.28 2.73% 21.01%
Veracyte 25.13 0.60 2.45% -19.56%
Vertex Pharmaceuticals 323.10 3.12 0.98% 27.42%

Indexes Price Day Year
USND 11585 190.74 1.67% -19.25%
US2000 1932 46.22 2.45% -5.79%

Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology company. The Company is focused in developing pharmacological agents for patients suffering from pain or cancer. Its oncology care product portfolio consists of SUSTOL and CINVANTI. Its SUSTOL (granisetron) is an extended-release, injectable used in the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Its CINVANTI, in combination with other antiemetic agents is used in the prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy (HEC). The Company's acute care product portfolio consist of ZYNRELEF (HTX-011) HTX-034, and HTX-019. The ZYNRELEF (HTX-011) is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.